One state Supreme Court case could destroy the court for years to come
The latest scheme to overturn voters’ will could set absurd precedents and irreparably harm our judicial system.
Excerpt:
It would be outrageous.
It would be unprecedented.
It would damage the credibility and validity of North Carolina’s highest court for decades.
It would be nothing short of a bloodless coup d’état by the Democrat majority on the state Supreme Court that would bloody North Carolina’s judiciary for years to come.
It would be a lawless decision, driven solely by politics.
It would render 9.6 million legally cast votes by North Carolina citizens meaningless.
It is likely to happen.
In an astonishing and unprecedented power grab that will overturn 200 years of case law and prior precedents, Democrats on the state Supreme Court are preparing to disqualify and remove two duly-elected Republican Supreme Court justices from a case so they can nullify voters’ decision to amend the Constitution.
The case is NAACP v. Moore and the state Supreme Court’s Democrats are trying to remove two Republican members from the bench, so a new temporary four-to-one Democrat majority can erase two constitutional amendments – the cap on income tax, and the voter I.D. requirement – which were overwhelmingly passed by more than four million votes.
Third of cancer drugs without proven clinical benefit continue to be recommended for patients
https://medicalxpress.com/news/2021-09-cancer-drugs-proven-clinical-benefit.html
Excerpt:
One third of cancer drugs that received accelerated approval from the US Food and Drug Administration (FDA) continue to be recommended in clinical guidelines after their confirmatory clinical trials fail to show improvement on their primary endpoints, finds a study published by The BMJ today.
A primary endpoint is the main result that is measured at the end of a study to see if a given treatment has worked (eg. the number of deaths or the difference in survival between the treatment group and the control group). What the primary endpoint will be is decided before the study begins.
The researchers say clinical guidelines “should better align with the results of post-approval trials of cancer drugs that received accelerated approval.”
The FDA’s accelerated approval pathway allows drugs onto the market before their effectiveness has been proven to hasten patients’ access to promising new drugs. But as part of this approval, the manufacturer must conduct post-approval trials to confirm clinical benefit (improved survival or quality of life in the case of cancer drugs). If these trials show no benefit, the drug’s approval can be withdrawn.
However, post-approval trials can be delayed for several years, and the FDA has until very recently been slow in taking steps to withdraw the drug or indication when these trials are conducted and fail to demonstrate clinical benefit.
....They searched the FDA database for all cancer drugs granted accelerated approval from the start of the program in 1992 until December 2020 and identified 18 indications for 10 cancer drugs that failed to show clinical benefit in post-approval trials.
The researchers then reviewed the latest FDA and National Comprehensive Cancer Network (NCCN) guidelines and found that most of these drugs continued to receive high level endorsement, sometimes even after approval for the given indication had been withdrawn or revoked.